IRCT201112036027N2 IRCT 2012-02-18 Tehran University of Medical sciences The effect of Topiramate on weight loss in Iranian patients with diabetes type 2 The effect of Topiramate on weight loss in Iranian patients with diabetes type 2 2008-10-01 anticipated 80 Complete https://irct.ir/trial/6493 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment. 3 Obesity. Intervention 1: Intervention: The 3-week titration phase began with administration of 25mg topiramate once every morning to subjects assigned to that group. In the second week, topiramate was administered at 25mg twice daily (50 mg/day). The dose was thereafter increased to 100 mg/day (50 mg in the morning and 50 mg in the evening). The maintenance phase began in the 4th week with the dose of 150mg/day. Finally the dose was tapered to 75 mg/day in the first week and 25mg/day in the second week up to either completion of or early withdrawal from the study. Intervention 2: Control:The 3-week titration phase began with administration of 25mg placebo tablet( prduced by Arya pharmacy company) that had shape and cover similar to topiramate tablets once every morning to subjects assigned to this group. In the second week, placebo tablet was administered at 25mg twice daily (50 mg/day). The dose was thereafter increased to 100 mg/day (50 mg in the morning and 50 mg in the evening). The maintenance phase began in the 4th week with the dose of 150mg/day. During the maintenance phase, the dose remained constant . Finally the dose was tapered to 75 mg/day in the first week and 25mg/day in the second week up to either completion of or early withdrawal from the study.